- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
Status
Completed
Phase
Demo Project
Principal Investigator(s)
National Institute of Allergy and Infectious Diseases of the NIH
Objective
Aims to enroll 600 HIV-negative MSM and transgender women for PrEP regimen at City Clinic, in Miami, and Whitman Walker Clinic.
**Results presented in July 2015 show high PrEP adherence and low HIV incidence. The study also showed that STIs were common among the participants, though STIs did not increase over the course of the study, highlighting the importance of STI screening and treatment among people using PrEP.**
Prevention Option(s)
PrEP
Study Design
Controlled
Arms and Assigned Interventions
Description
Aims to enroll 300 HIV-negative MSM and transgender women at City Clinic, while a sister project in Miami will enroll 200 participants in a PrEP regimen. Whitman Walker Clinic in Washington, DC, will also be a site, aiming to enroll approximately 100 participants.
Mode of Delivery
Tablet
Products
TDF/FTC (Truvada)
ARMs
Experimental
Trial Sponsors
National Institute of Allergy and Infectious Diseases of the NIH
Product Developers
National Institute of Allergy and Infectious Diseases of the NIH
October 2014
January 2015
Enrollment
600
18
Years
Population
MSM
Sites
Site(s) - United States
United States of America
Whitman Walker Clinic
Washington, D.C.
United States of America
City Clinic
United States of America